Synkavit. Radiosensitizing agent in prostatic carcinoma.
D000135:Acid Phosphatase / Q000378:metabolism; D000273:Adipose Tissue / Q000032:analysis; D000818:Animals; D000882:Haplorhini; D006868:Hydrolysis; D007275:Injections, Intravenous; D007422:Intestines / Q000032:analysis; D008099:Liver / Q000032:analysis; D008297:Male; D009132:Muscles / Q000032:analysis; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000378:metabolism; D011467:Prostate / Q000032:analysis; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000378:metabolism*; D013154:Spleen / Q000032:analysis; D013737:Testis / Q000032:analysis; D014316:Tritium; D001743:Urinary Bladder / Q000032:analysis; D014812:Vitamin K / Q000032:analysis / Q000652:urine
D009943:Organophosphorus Compounds; D011838:Radiation-Sensitizing Agents; D014316:Tritium; D014812:Vitamin K; D000135:Acid Phosphatase